Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/targeting-epigenetic-modifications-for-the-treatment-and-prevention-of-DPgDxYIwzf
References (52)
-
M. Candelaria, D. Gallardo-Rincón, C. Arce, L. Cetina, J. Aguilar-Ponce, O. Arrieta, A. Serrano, C. Pérez-Plasencia, A. González-Fierro, Erik Cruz-Hernandez, A. Revilla-Vázquez, A. Chávez-Blanco, C. Trejo-Becerril, E. Pérez-Cárdenas, L. Taja-Chayeb, M. Camargo, E. Robles, A. Dueñas-González (2007)
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumorsBMC Cancer, 7
-
M. Campone, P. Conte, D. Amadori, P. Pronzato, A. Wardley, K. McBride, A. Fandi (2009)
Phase I Trial of Panobinostat (LBH589) in Combination with Trastuzumab in Pretreated HER2-Positive Metastatic Breast Cancer (mBC): Preliminary Safety, Efficacy and Pharmacokinetic Results.Cancer Research, 69
-
A. Munshi, Toshimitsu Tanaka, M. Hobbs, S. Tucker, V. Richon, R. Meyn (2006)
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX fociMolecular Cancer Therapeutics, 5
-
Jeffrey Kovacs, P. Murphy, S. Gaillard, Xuan Zhao, June-Tai Wu, C. Nicchitta, Minoru Yoshida, D. Toft, W. Pratt, T. Yao (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.Molecular cell, 18 5
-
Pang-Kuo Lo, J. Mehrotra, A. D'costa, M. Fackler, E. Garrett-Mayer, P. Argani, S. Sukumar (2006)
Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancerCancer Biology & Therapy, 5
-
P. Munster, A. Daud, Anthony Neuger, S. Minton, D. Sullivan, Pamela Mu
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/ii Trial of Valproic Acid and Epirubicin/fec Cancer Therapy: Clinical -
M. Widschwendter, Peter Jones (2002)
DNA methylation and breast carcinogenesisOncogene, 21
-
A. Weiss, J. Stambaugh, M. Mastrangelo, J. Laucius, R. Bellet (1972)
Phase I study of 5-azacytidine (NSC-102816) .Cancer chemotherapy reports, 56 3
-
Elizabeth Cameron, K. Bachman, S. Myöhänen, J. Herman, S. Baylin (1999)
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancerNature Genetics, 21
-
M. Fackler, K. Malone, Zhe Zhang, Eric Schilling, E. Garrett-Mayer, T. Swift-Scanlan, J. Lange, R. Nayar, N. Davidson, S. Khan, S. Sukumar (2006)
Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal FluidClinical Cancer Research, 12
-
Weiss Aj, Metter Ge, Nealon Tf, Keanan Jp, Guillermo Ramirez, A. Swaiminathan, William Fletcher, Scot Moss, Manthei Rw (1977)
Phase II study of 5-azacytidine in solid tumors.Cancer treatment reports, 61 1
-
Peter Jones, Shirley Taylor (1980)
Cellular differentiation, cytidine analogs and DNA methylationCell, 20
-
A. Mai, L. Altucci (2009)
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.The international journal of biochemistry & cell biology, 41 1
-
P. Marks, V. Richon, W. Kelly, J. Chiao, Thomas Miller (2004)
Histone deacetylase inhibitors: development as cancer therapy.Novartis Foundation symposium, 259
-
Qun Zhou, P. Atadja, N. Davidson (2007)
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylationCancer Biology & Therapy, 6
-
N. Peacock, Suzanne Jones, D. Yardley, J. Bendell, J. Infante, P. Murphy, H. Burris (2010)
A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.Journal of Clinical Oncology, 28
-
J. Herman, S. Baylin (2003)
Gene silencing in cancer in association with promoter hypermethylation.The New England journal of medicine, 349 21
-
Shiuan Chen, Jingjing Ye, I. Kijima, D. Evans (2010)
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expressionProceedings of the National Academy of Sciences, 107
-
M. Glozak, N. Sengupta, Xiaohong Zhang, E. Seto (2005)
Acetylation and deacetylation of non-histone proteins.Gene, 363
-
P. Jones (2003)
Epigenetics in Carcinogenesis and Cancer PreventionAnnals of the New York Academy of Sciences, 983
-
P. Munster, M. Lacevic, S. Thomas, C. Christian, R. Ismail-Khan, M. Melisko, H. Rugo, S. Minton (2016)
Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
V. Stearns, L. Jacobs, T. Tsangaris, Z. Cheng, S. Slater, M. Fackler, C. Chao, R. Bugarini, E. Gabrielson, N. Davidson (2010)
Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.Journal of Clinical Oncology, 28
-
E. Evron, W. Dooley, C. Umbricht, D. Rosenthal, N. Sacchi, E. Gabrielson, A. Soito, David Hung, B. Ljung, N. Davidson, S. Sukumar (2001)
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCRThe Lancet, 357
-
P Munster, D Marchion, E Bicaku (2009)
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FECClin Cancer Res, 15
-
G. Sabnis, O. Goloubeva, R. Gilani, N. Nguyen, S. Chumsri, L. Macedo, S. Sukumar, A. Brodie (2009)
Expression of ERα and Aromatase in MDA-MB-231 Tumors by HDAC Inhibitor Entinostat Leads to Growth Inhibition by Aromatase Inhibitor Letrozole.Cancer Research, 69
-
Jonathan Cheng, C. Yoo, D. Weisenberger, Jody Chuang, C. Wozniak, G. Liang, V. Marquez, S. Greer, T. Orntoft, T. Thykjaer, Peter Jones (2004)
Preferential response of cancer cells to zebularine.Cancer cell, 6 2
-
J. Christman (2002)
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapyOncogene, 21
-
A. Wardley, R. Stein, J. McCaffrey, J. Crown, Z. Malik, D. Rea, P. Barrett-Lee, G. Lee (2010)
Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy.Journal of Clinical Oncology, 28
-
A. Baschnagel, A. Russo, W. Burgan, Donna Carter, K. Beam, D. Palmieri, P. Steeg, P. Tofilon, K. Camphausen (2009)
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenograftsMolecular Cancer Therapeutics, 8
-
L. Mell, J. Dignam, J. Salama, E. Cohen, B. Polite, V. Dandekar, A. Bhate, M. Witt, D. Haraf, B. Mittal, E. Vokes, R. Weichselbaum (2010)
Predictors of competing mortality in advanced head and neck cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
-
PA Jones (2003)
Epigenetics in carcinogenesis and cancer preventionAnn NY Acad Sci, 983
-
PD Yang, AT Ferguson (2001)
Synergistic activation of of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibtion in human ER-alpha-nagative breast cancer cellsCancer Res, 2001
-
Lianne Fuino, P. Bali, S. Wittmann, S. Donapaty, F. Guo, H. Yamaguchi, Hong-Gang Wang, P. Atadja, K. Bhalla (2003)
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.Molecular cancer therapeutics, 2 10
-
A. Bird (2007)
Perceptions of epigeneticsNature, 447
-
P. Munster, D. Marchion, S. Thomas, M. Egorin, S. Minton, G. Springett, Ji Lee, G. Simon, A. Chiappori, D. Sullivan, A. Daud (2009)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive markerBritish Journal of Cancer, 101
-
D. Sharma, N. Saxena, N. Davidson, P. Vertino (2006)
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.Cancer research, 66 12
-
M. Esteller (2007)
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes.British journal of cancer, 96 Suppl
-
P. Murphy, Y. Morishima, Jeffrey Kovacs, T. Yao, W. Pratt (2005)
Regulation of the Dynamics of hsp90 Action on the Glucocorticoid Receptor by Acetylation/Deacetylation of the Chaperone*Journal of Biological Chemistry, 280
-
T. Luu, R. Morgan, L. Leong, D. Lim, M. McNamara, J. Portnow, P. Frankel, David Smith, J. Doroshow, D. Gandara, A. Aparicio, G. Somlo, Carol Wong (2008)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium StudyClinical Cancer Research, 14
-
D. Marchion, E. Biçaku, A. Daud, V. Richon, D. Sullivan, P. Munster (2004)
Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidJournal of Cellular Biochemistry, 92
-
SS Sharma, NE Davidson, PM Vertino (2006)
Restoration of tamoxifen sensitivity in ER negative breast cancer cells: tamoxifen-bound reactivated estrogen receptor recruits distinctive corepressor complexesCancer Res, 66
-
M Candelaria, D Gallardo-Rincon, C Arce (2007)
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumorsAnn Oncol, 18
-
A. Stathis, S. Hotte, H. Hirte, E. Chen, S. Webster, A. Iacobucci, S. McGill, L. Wang, I. Espinoza‐Delgado, L. Siu (2016)
Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
R. Connolly, S. Jeter, J. Zorzi, Zhen Zhang, D. Armstrong, J. Fetting, A. Wolff, M. Goetz, A. Storniolo, V. Stearns (2010)
A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008).Journal of Clinical Oncology, 28
-
T. Bestor (1998)
Gene silencing: Methylation meets acetylationNature, 393
-
L Fuino, S Wittman (2003)
Histone deacetylse inhibitor LAQ824 down regulated Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothiloneB Mol Cancer Ther, 2
-
S. Baylin, J. Ohm (2006)
Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nature Reviews Cancer, 6
-
P. Marks, Xuejun Jiang (2005)
Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer TherapyCell Cycle, 4
-
C. Arce, C. Pérez-Plasencia, A. González-Fierro, E. cruz-Hernandez, A. Revilla-Vázquez, A. Chávez-Blanco, C. Trejo-Becerril, E. Pérez-Cárdenas, L. Taja-Chayeb, E. Bargalló, P. Villarreal, T. Ramírez, T. Vela, M. Candelaria, M. Camargo, E. Robles, A. Dueñas-González (2006)
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast CancerPLoS ONE, 1
-
Y. Lawrence, R. Pfeffer, M. Werner-Wasik, H. Choy, A. Dicker (2010)
Combination of vorinostat with whole-brain radiotherapy in the treatment of brain metastases.Journal of Clinical Oncology, 28
-
I. Locke, Z. Kote-Jarai, Mary Fackler, E. Bancroft, P. Osin, A. Nerurkar, L. Izatt, G. Pichert, G. Gui, R. Eeles (2007)
Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controlsBreast Cancer Research, 9
-
E. Ho, J. Clarke, R. Dashwood (2009)
Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention.The Journal of nutrition, 139 12
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Surgical Oncology; Internal Medicine; Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-010-0027-z
- Publisher site
- See Article on Publisher Site
Abstract
DNA methylation, histone modification, and nucleosome remodeling are the three intercalated events that result in epigenetic modification, which in turn alters gene expression. Aberrant epigenetic regulation resulting in altered gene expression has been clearly implicated in the initiation and progression of breast cancer. Our understanding of the landscape of these changes in breast cancer has increased tremendously over the past decade. Significant advancement has been made in the preclinical arena to identify targets that are epigenetically altered in breast cancer and to modulate these targets with epigenetic therapies to improve tumor response. Clinical translation of these concepts is currently ongoing and shows promise in improving outcomes in breast cancer. This article provides a comprehensive review of the completed and ongoing clinical trials of epigenetic therapy in the management and prevention of breast cancer and the rationale leading to the design of these trials.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Oct 8, 2010